# The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

> **NCT05841550** · PHASE1,PHASE2 · RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma
- Smoldering Multiple Myeloma

## Interventions

- **BIOLOGICAL:** TG01

## Key facts

- **NCT ID:** NCT05841550
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-19
- **Primary completion:** 2027-05-19
- **Final completion:** 2035-05-19
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841550, "The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05841550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*